jarid2b Antibody

What is JARID2 and what is its biological function?

JARID2 (Jumonji/ARID domain-containing protein 2) functions as a regulator of histone methyltransferase complexes with essential roles in embryonic development, including heart and liver development, neural tube fusion, and hematopoiesis. It serves as an accessory subunit for the core PRC2 (Polycomb repressive complex 2) complex, mediating histone H3K27 (H3K27me3) trimethylation on chromatin. JARID2 binds DNA and recruits the PRC2 complex to target genes in embryonic stem cells, playing a critical role in stem cell differentiation and normal embryonic development . In cardiac cells, JARID2 represses cyclin-D1 (CCND1) expression by activating methylation of histone H3K9 through GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases. It also functions as a transcriptional repressor of ANF through interactions with GATA4 and NKX2-5, and participates in negative regulation of cell proliferation signaling .

What types of JARID2 antibodies are available for research?

Several types of JARID2 antibodies are available for research applications, including:

These antibodies vary in their format, applications, and the epitopes they recognize, allowing researchers to select the most appropriate option for their specific experimental needs .

What are the common applications for JARID2 antibodies?

JARID2 antibodies are employed across multiple experimental techniques in epigenetic and developmental biology research:

• Western Blotting (WB): For detecting JARID2 protein expression levels in cell or tissue lysates, with an expected molecular weight of approximately 150 kDa .

• Immunocytochemistry/Immunofluorescence (ICC/IF): For visualizing JARID2 subcellular localization in fixed cells .

• Immunoprecipitation (IP): For isolating JARID2 protein complexes to study protein-protein interactions .

• Chromatin Immunoprecipitation (ChIP): For identifying genomic regions where JARID2 binds, helping elucidate its role in transcriptional regulation .

• Advanced Chromatin Profiling (CUT&RUN, CUT&Tag): For higher resolution mapping of JARID2 genomic binding sites with improved signal-to-noise ratio compared to traditional ChIP .

These applications allow researchers to comprehensively study JARID2's expression, localization, interactions, and genomic binding patterns.

How should I choose between polyclonal, multiclonal, and monoclonal JARID2 antibodies?

The choice depends on your experimental requirements:

Polyclonal antibodies (e.g., ab184152) recognize multiple epitopes on JARID2, potentially providing higher sensitivity but with greater batch-to-batch variation. These are useful for applications where signal amplification is important .

Multiclonal antibodies (e.g., ab308119) offer a middle ground, with controlled heterogeneity that provides good sensitivity while reducing batch variation compared to traditional polyclonals .

Monoclonal antibodies (e.g., D6M9X) recognize a single epitope, offering highest specificity and consistency between experiments. These are ideal for applications requiring high reproducibility, such as ChIP and advanced chromatin profiling techniques .

For critical experiments, consider validating findings with multiple antibody types to ensure robust results. The recombinant nature of newer antibodies like D6M9X offers superior lot-to-lot consistency, continuous supply, and animal-free manufacturing compared to traditional production methods .

How should I validate a JARID2 antibody for my specific application?

Comprehensive validation is essential before using JARID2 antibodies in critical experiments:

• Positive and negative controls: Use cell lines or tissues known to express JARID2 (positive control) and those with low/no expression or JARID2 knockout samples (negative control).

• Cross-reactivity assessment: Test antibody performance against related proteins, particularly other Jumonji family members, to ensure specificity.

• Application-specific validation:

  • For WB: Verify single band at expected molecular weight (150 kDa)

  • For ICC/IF: Compare staining pattern with published subcellular localization

  • For ChIP/CUT&RUN/CUT&Tag: Validate binding at known JARID2 target sites

• Antibody dilution optimization: Test multiple dilutions to determine optimal signal-to-noise ratio for your specific sample type and application.

• Reproducibility testing: Ensure consistent results across multiple experiments and sample preparations.

For advanced applications, consider combining antibody-based detection with orthogonal techniques (e.g., mRNA expression analysis) to strengthen research findings .

What are the optimal protocols for using JARID2 antibodies in chromatin immunoprecipitation (ChIP)?

When using JARID2 antibodies for ChIP experiments, follow these methodological guidelines:

• Antibody selection: Monoclonal antibodies like D6M9X are preferred for ChIP applications due to higher specificity and reproducibility .

• Antibody amount: For standard ChIP protocols, use approximately 1-6 µg of antibody per chromatin preparation from 4-10 million cells .

• Chromatin preparation:

  • Crosslink cells with 1% formaldehyde for 10 minutes at room temperature

  • Fragment chromatin to 200-500 bp using sonication or enzymatic digestion

  • Verify fragmentation efficiency by agarose gel electrophoresis

• Immunoprecipitation conditions:

  • Pre-clear chromatin with protein A/G beads

  • Incubate with JARID2 antibody overnight at 4°C

  • Capture antibody-chromatin complexes with protein A/G beads

  • Perform stringent washes to remove non-specific binding

• Controls: Include IgG control and input samples for normalization and background assessment.

• Validation regions: Target analysis to known JARID2-binding regions as positive controls.

For advanced applications, consider using the SimpleChIP® Enzymatic Chromatin IP Kits with the D6M9X antibody, which has been specifically validated for this system .

What are the advantages of CUT&RUN and CUT&Tag compared to traditional ChIP for JARID2 studies?

CUT&RUN and CUT&Tag represent significant methodological advances for studying JARID2 genomic localization:

The D6M9X JARID2 antibody has been validated for both CUT&RUN and CUT&Tag applications, with recommended dilutions optimized for the CUT&RUN Assay Kit #86652 and CUT&Tag Assay Kit . These approaches provide several advantages for JARID2 research:

• Higher sensitivity: Detect JARID2 binding with fewer cells and less antibody

• Improved resolution: Map binding sites with greater precision

• Reduced background: Better distinction between true binding sites and noise

• Faster protocols: Complete experiments in less time

These advantages make CUT&RUN and CUT&Tag particularly valuable for studying JARID2's role in chromatin regulation during development or in rare cell populations where material is limited .

How can computational models enhance the design of specific JARID2 antibodies?

Advanced computational modeling approaches can significantly improve JARID2 antibody specificity and performance:

• Binding mode identification: Computational models can identify different binding modes associated with specific ligands, enabling the prediction and generation of antibody variants with customized specificity profiles that go beyond those observed in experimental selections .

• Biophysics-informed modeling: By training models on experimentally selected antibodies and associating distinct binding modes with potential ligands, researchers can predict outcomes for novel ligand combinations and generate antibody variants with tailored specificity .

• Cross-reactivity prediction: Models can simulate antibody interactions with related proteins (e.g., other Jumonji family members) to identify sequences that maximize JARID2 specificity while minimizing off-target binding .

• Epitope optimization: Computational approaches can identify optimal epitopes within JARID2 that are:

  • Highly specific to JARID2 versus related proteins

  • Accessible in native protein conformations

  • Stable across different experimental conditions

• Library design enhancement: For researchers developing new JARID2 antibodies, computational models can guide the design of antibody libraries with increased likelihood of yielding specific binders .

This computational approach has been successfully demonstrated in antibody development, where models trained on phage display data successfully disentangled different binding modes, even when associated with chemically similar ligands .

How can JARID2 antibodies be used to study PRC2 complex recruitment in stem cells?

JARID2 antibodies are invaluable tools for investigating the mechanisms of PRC2 recruitment to target genes in stem cells:

• Co-immunoprecipitation (Co-IP): Use JARID2 antibodies to pull down JARID2 and associated PRC2 complex components (EZH2, SUZ12, EED) to study complex composition and stoichiometry in different stem cell states.

• Sequential ChIP (ChIP-reChIP): Perform initial ChIP with JARID2 antibody followed by second ChIP with antibodies against other PRC2 components to identify genomic sites where the complete complex is bound.

• ChIP-seq comparative analysis: Compare genome-wide binding profiles of JARID2 with other PRC2 components to identify:

  • Sites where JARID2 and PRC2 co-localize

  • JARID2-only sites (potential PRC2 recruitment sites)

  • PRC2-only sites (JARID2-independent binding)

• CUT&RUN or CUT&Tag time course experiments: Monitor the temporal dynamics of JARID2 and PRC2 recruitment during stem cell differentiation using the D6M9X antibody validated for these techniques .

• Proximity ligation assays (PLA): Visualize and quantify in situ interactions between JARID2 and PRC2 components at the single-cell level during differentiation.

These approaches leverage JARID2 antibodies to elucidate how JARID2 mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells, playing a key role in stem cell differentiation and normal embryonic development .

What methodological considerations are important when using JARID2 antibodies in developmental studies?

When studying JARID2's role in embryonic development, researchers should consider several methodological aspects:

• Developmental stage-specific optimization: JARID2 expression and function vary across developmental stages. Optimize antibody concentrations and experimental conditions for each developmental timepoint.

• Tissue-specific considerations:

  • Heart and liver development: Focus on JARID2's role in tissue-specific gene repression

  • Neural tube fusion: Examine JARID2's interaction with neural-specific transcription factors

  • Hematopoiesis: Investigate JARID2's function in blood cell lineage specification

• Species compatibility: Confirm antibody cross-reactivity with your model organism. Available JARID2 antibodies are validated for human and mouse samples , but additional validation is required for other species.

• Isoform awareness: Be cognizant of potential JARID2 isoforms expressed during development and ensure your selected antibody recognizes the relevant isoform(s).

• Combinatorial approaches: Combine antibody-based detection with genetic approaches (e.g., conditional knockouts) to establish causality in developmental phenotypes.

• Single-cell applications: For heterogeneous developmental contexts, consider adapting techniques for single-cell resolution (e.g., imaging mass cytometry with JARID2 antibodies).

These considerations help ensure robust and reproducible results when investigating JARID2's essential roles in heart and liver development, neural tube fusion, and hematopoiesis .

What are common sources of false positives/negatives with JARID2 antibodies?

Understanding potential sources of error is critical for accurate data interpretation:

Sources of false positives:

• Cross-reactivity with related proteins: JARID2 belongs to the Jumonji family, which includes multiple members with similar domains. Antibodies may cross-react with related proteins, particularly JARID1 family members.

• Non-specific binding: High antibody concentrations or insufficient blocking can lead to non-specific signals, particularly in immunostaining applications.

• Secondary antibody cross-reactivity: Secondary antibodies may bind endogenous immunoglobulins in tissue samples, especially when using the same species for primary antibody generation and sample origin.

• Post-translational modifications: Some antibodies may differentially recognize modified forms of JARID2, leading to inconsistent results across sample types with different modification patterns.

Sources of false negatives:

• Epitope masking: Protein-protein interactions or conformational changes may obscure the epitope recognized by the antibody.

• Fixation sensitivity: Some epitopes may be destroyed or altered by certain fixation methods, particularly relevant for immunostaining applications.

• Low expression levels: JARID2 expression varies across cell types and developmental stages; low expression may require more sensitive detection methods.

• Protocol inadequacies: Suboptimal permeabilization, antigen retrieval, or antibody dilution can reduce detection efficiency.

To mitigate these issues, always include appropriate positive and negative controls, validate with multiple antibodies when possible, and optimize protocols for your specific experimental context .

How can I address contradictory results between different JARID2 antibodies?

When facing discrepancies between results obtained with different JARID2 antibodies, follow this systematic approach:

• Epitope mapping comparison: Identify the specific regions of JARID2 recognized by each antibody. Different antibodies may detect different isoforms or post-translationally modified forms of JARID2.

• Validation with orthogonal methods: Confirm JARID2 presence/absence using non-antibody-based approaches:

  • mRNA expression analysis (RT-qPCR, RNA-seq)

  • Mass spectrometry-based protein identification

  • CRISPR/Cas9-mediated tagging of endogenous JARID2

• Cross-validation with multiple antibodies: Test additional JARID2 antibodies with different clonality and epitope recognition:

  • Polyclonal ab184152 (recognizes aa 650-900)

  • Multiclonal ab308119

  • Monoclonal D6M9X mAb #13594

• Application-specific optimization: Different antibodies may perform optimally in specific applications. For instance:

  • Some antibodies may work well for Western blot but poorly for immunoprecipitation

  • Others may excel in fixed tissue immunostaining but fail in live-cell applications

• Lot-to-lot variation assessment: For polyclonal antibodies, significant batch variation can occur. Recombinant antibodies like D6M9X offer superior lot-to-lot consistency .

• Literature comparison: Examine which antibodies were used in published studies with similar experimental systems and what validation was performed.

By systematically evaluating these factors, researchers can determine the most reliable antibody for their specific experimental system and clarify contradictory results .

What are the current limitations of JARID2 antibodies in research applications?

Despite their utility, current JARID2 antibodies have several limitations researchers should consider:

• Isoform discrimination: Most available antibodies cannot effectively distinguish between potential JARID2 isoforms or splice variants, limiting studies of isoform-specific functions.

• Post-translational modification detection: Current antibodies generally cannot discriminate between different post-translationally modified forms of JARID2, obscuring potential regulatory mechanisms.

• Species cross-reactivity constraints: Most validated JARID2 antibodies are confirmed only for human and mouse samples , limiting studies in other model organisms without additional validation.

• Conformational state detection: Available antibodies may preferentially recognize certain conformational states of JARID2, potentially missing important functional states within the PRC2 complex.

• Live-cell application limitations: Most JARID2 antibodies are validated for fixed samples, with limited options for live-cell imaging applications that could reveal dynamic behaviors.

• Quantitative limitations: While antibodies can detect JARID2 presence, precise quantification remains challenging due to potential epitope masking and variable accessibility in different cellular contexts.

Researchers are addressing these limitations through computational approaches to design antibodies with customized specificity profiles and the development of alternative detection methods that complement traditional antibody-based approaches .

How can computational approaches improve antibody specificity for complex targets like JARID2?

Advanced computational methods are transforming antibody development for challenging targets like JARID2:

• Multi-modal binding analysis: Computational models can identify distinct binding modes associated with specific targets, enabling the design of antibodies with customized specificity profiles that go beyond those observed in experimental selections .

• Predictive generation: Biophysics-informed models trained on experimental data can predict outcomes for new ligand combinations and generate antibody variants with tailored specificity profiles that were not present in the initial library .

• Experimental-computational hybrid approaches: The most promising strategy combines:

  • High-throughput experimental selection against diverse ligand combinations

  • Computational modeling to disentangle binding modes

  • In silico optimization of antibody sequences

  • Experimental validation of computationally designed variants

This approach has demonstrated success in designing antibodies with customized specificity profiles, either with specific high affinity for particular target ligands or with cross-specificity for multiple target ligands .

• Epitope-focused design: Computational approaches can identify optimal epitopes within JARID2 that maximize distinguishing features from related proteins.

• Artificial intelligence integration: Machine learning algorithms trained on antibody-antigen interaction data can predict binding properties and guide rational design of improved JARID2 antibodies.

These computational methods help address the challenges of antibody specificity, particularly for discriminating between JARID2 and related Jumonji family proteins or detecting specific JARID2 conformational states .

What are the latest applications of JARID2 antibodies in epigenetic research?

JARID2 antibodies are enabling several cutting-edge applications in epigenetic research:

• Single-cell epigenomic profiling: Adaptation of CUT&Tag protocols using JARID2 antibodies for single-cell analysis reveals cell-to-cell variability in PRC2 recruitment and function during development and disease.

• Multi-omics integration: Combining JARID2 ChIP-seq or CUT&RUN with RNA-seq, ATAC-seq, and histone modification profiling to create comprehensive maps of regulatory networks controlled by JARID2-mediated PRC2 recruitment.

• Spatial epigenomics: Utilizing JARID2 antibodies in emerging spatial technologies to map PRC2 complex distribution across tissues while preserving spatial context.

• In vivo chromatin dynamics: Adaptation of JARID2 antibodies for in vivo footprinting approaches to monitor dynamic changes in JARID2-chromatin interactions during development or in response to environmental stimuli.

• Proximity proteomics: Using JARID2 antibodies in conjunction with proximity labeling techniques (BioID, APEX) to identify novel interaction partners in different cellular contexts.

• Therapeutic targeting assessment: Evaluating how emerging epigenetic therapies affect JARID2 recruitment and function using validated antibodies in preclinical models.

These applications leverage the specificity of antibodies like D6M9X and the versatility of new techniques like CUT&RUN and CUT&Tag to provide unprecedented insights into JARID2's role in epigenetic regulation .